Intellia's Groundbreaking CRISPR Therapy Receives FDA Priority Review
Intellia's lonvoguran ziclumeran receives FDA Priority Review, positioning NTLA as a leader in CRISPR gene editing.
Intellia Therapeutics Advances with FDA Priority Review for Groundbreaking CRISPR Therapy
Intellia Therapeutics secures FDA Priority Review for its CRISPR therapy, potentially transforming t…
Sernova and Seraxis Merge to Form BetaNova Biotherapeutics: A New Player in Type 1 Diabetes Treatment
Sernova and Seraxis merge to create BetaNova, a company poised to innovate in Type 1 diabetes treatm…
International Petroleum Corp Executes Share Buyback as North American Markets Go Dark for Labor Day
IPCO repurchased 140,673 shares under its NCIB while US and Canadian equities closed for Labor Day. …
Oil Holds Near Six-Week Highs as US-Iran Conflict Rattles Energy Markets and Inflation Outlook
Oil prices remain elevated near six-week highs as US-Iran military exchanges disrupt Strait of Hormu…
Merck-Moderna mRNA Cancer Vaccine Hits Phase 3 Melanoma Endpoints, Boosting Both Stocks' Oncology Pipelines
The INTerpath-001 Phase 3 trial of intismeran autogene plus KEYTRUDA met co-primary endpoints in mel…
Amazon Prime Air Crash in Miami Raises Questions on Logistics Safety and Regulatory Oversight
An Amazon Prime Air cargo plane crashed in Miami on September 6, killing at least five people. The i…
International Petroleum Corporation Completes Weekly Share Buyback Under TSX Normal Course Issuer Bid
IPC repurchased 140,673 common shares during September 1–4, 2026, under its NCIB program. The dual-l…
Oil Holds 6-Week Highs as Persian Gulf Tensions Threaten US Inflation Outlook
Oil prices remain elevated near 6-week highs amid US-Iran military tensions choking Hormuz Strait tr…
China's Rare Earth Cutoff: Why US Domestic Miners Could Be the Real Winners
China halts US-bound rare earth shipments amid geopolitical tensions, positioning domestic producers…